Randomized trial with over 30.000 patients showed AstraZeneca vaccine was safe and resulted in 74% efficacy against symptomatic SARS-CoV-2 infection.
30 Sep, 2021 | 10:32h | UTC
Commentaries on Twitter
In a phase 3 trial of the ChAdOx1 nCoV-19 vaccine in over 32,000 participants the incidence of serious adverse effects was low and the vaccine efficacy was 74%. Efficacy was documented in a range of demographic subgroups. #Covid19vaccine https://t.co/hK8q2dD6OT pic.twitter.com/58aXusCS4I
— NEJM (@NEJM) September 29, 2021
The pivotal trial of the Astra-Zeneca vaccine in over 32,000 participants, published today @NEJM.
Vaccine efficacy 74% [95% CI 65,80] vs symptomatic infections; maintained across subgroups,
age > 65: 84% [54,84] https://t.co/ou3nb15Khx pic.twitter.com/dlwRnrvyc0— Eric Topol (@EricTopol) September 29, 2021